Pharma Intensifies Collaborative Research with Academia
The nascent trend of five years ago is rapidly becoming the model of today. More & more pharma research is focused on joining forces with universities. The rationale is simple and brilliant; With the ever escalating costs of R & D and the ‘patent cliff’ fast approaching, the merger of resources is a natural wellspring of mutual benefits.
Big pharma needs new drug discoveries and more cost effective ways of discovering them. 80% of all FDA approved drugs have generic counter-parts, according to the 2010 Kaiser Foundation report on prescription drug trends. Add to this the fast approaching edge of the “patent cliff” (2011-2015) when dozens of brand name drugs go off patent, including six of the ten largest medicines in the U.S. and you get a good idea of the challenges facing the ‘business’ of big pharma. Viagara, Actos, Symbicort, Crestor and Avandia are just a few major brands to face generic competition soon.
Partnering with universities will offer big pharma alternate approaches to their on-going research…access to new and experimental technologies, creative thought processes indigenous to the university environment…more cost efficient continued development of in-license drug candidates…fresh stimulus for stalled projects…the potential of discovering multiple, new applications for existing drugs…all in an arena that could offer new, more rapid research platforms for the discovery and release of better medicines.
In this win-win collaboration, universities will be able to analyze pharma’s extensive and diverse data…and data is what it’s all about in the research and development of new drugs. An example of this trend is Sanofi’s recent announcement to collaborate with Harvard in diabetes and cancer research. As pharma gleans new & improved information from institutional partners, so too do those institutions gain precious access to pharma’s previously locked treasure chest of health science research.
It’s a natural collaboration, taking place on a global scale. A marriage of necessity expected to bring forth a new generation of blockbuster progeny.